Piper Sandler analyst Edward Tenthoff reiterated a Buy rating on Legend Biotech (LEGN – Research Report) today and set a price target of $90.00. The company’s shares closed last Friday at $54.93.
Tenthoff covers the Healthcare sector, focusing on stocks such as Alnylam Pharma, Moderna, and Arrowhead Pharmaceuticals. According to TipRanks, Tenthoff has an average return of 1.3% and a 36.55% success rate on recommended stocks.
In addition to Piper Sandler, Legend Biotech also received a Buy from Barclays’s Gena Wang in a report issued today. However, on the same day, William Blair maintained a Hold rating on Legend Biotech (NASDAQ: LEGN).
The company has a one-year high of $77.32 and a one-year low of $48.37. Currently, Legend Biotech has an average volume of 963.9K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Legend Biotech (LEGN) Company Description:
Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm’s lead product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy is for the treatment of multiple myeloma. Its other pipeline products include LB1910, LB1909, LB1903, and others. Geographically, the company generates a majority of its revenue from North America.
Read More on LEGN:
- Legend’s CARVYKTI approved by FDA for second-line treatment of multiple myeloma
- Cantor starts Legend Biotech at Overweight on Carvykti expansion
- Legend Biotech initiated with an Overweight at Cantor Fitzgerald
- Legend Biotech Boosts Drug Production with Novartis
- Legend Biotech files automatic mixed securities shelf
